All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @gottafigurelikeagrandpa on TikTok · 15s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @gottafigurelikeagrandpa's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Thanks for watching guys!

@gottafigurelikeagrandpa's GLP-1 maintenance claims checked

Your grandfather

TikTok creator

436.3K viewsWatch on TikTok

Quick answer

GLP-1 receptor agonists like semaglutide and tirzepatide work by mimicking incretin hormones that regulate blood sugar and appetite. Clinical trials show 15-20% weight loss on treatment, but most patients regain 60-70% of lost weight within a year of stopping. Long-term maintenance typically requires continued medication use.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @gottafigurelikeagrandpa's GLP-1 maintenance claims checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

@gottafigurelikeagrandpa's GLP-1 maintenance claims checked is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@gottafigurelikeagrandpa's GLP-1 maintenance claims checked" from Your grandfather. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: GLP-1 receptor agonists like semaglutide and tirzepatide work by mimicking incretin hormones that regulate blood sugar and appetite.

The reason this review is not generic is the source wording and the canonical claim label "glp1 i hope i keep it lmao." In this clip, the useful excerpt is: "Thanks for watching guys!" That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

The STEP 4 withdrawal trial showed continued semaglutide users lost additional weight while those who stopped regained 6.
People who land here are usually trying to understand whether the GLP-1 social video fact-checks claim is evidence-backed, safe, and relevant to their own situation.
The strongest next step is to compare the claim with FormBlends' GLP-1 social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

GLP-1 receptor agonists like semaglutide and tirzepatide work by mimicking incretin hormones that regulate blood sugar and appetite.

FormBlends verdict

GLP-1 social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • GLP-1 receptor agonists like semaglutide and tirzepatide work by mimicking incretin hormones that regulate blood sugar and appetite. Clinical trials show 15-20% weight loss on treatment, but most patients regain 60-70% of lost weight within a year of stopping. Long-term maintenance typically requires continued medication use.
  • Patients who stop GLP-1 medications regain 60-70% of their weight loss within one year according to multiple clinical trials
  • The STEP 4 withdrawal trial showed continued semaglutide users lost additional weight while those who stopped regained 6.9% body weight

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • Patients who stop GLP-1 medications regain 60-70% of their weight loss within one year according to multiple clinical trials
  • The STEP 4 withdrawal trial showed continued semaglutide users lost additional weight while those who stopped regained 6.9% body weight
  • SURMOUNT-4 data demonstrates that tirzepatide patients who stopped treatment regained most weight while continuing patients maintained 20.9% weight reduction
  • Only about 20% of patients in STEP 1 maintained their full weight loss one year after stopping semaglutide
  • The SELECT cardiovascular outcomes trial suggests these medications work best as long-term treatments, not short-term fixes
  • Real-world electronic health record data shows two-year continuous users maintain significantly more weight loss than early discontinuation patients
  • Successful maintenance typically combines continued medication with lifestyle modifications rather than relying on hope alone

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What does this viral video actually claim?

@gottafigurelikeagrandpa's TikTok with 436K views shows him expressing hope about keeping his weight loss results while on GLP-1 medications. The brief video doesn't make specific medical claims but touches on a common concern: whether weight loss from drugs like semaglutide or tirzepatide is sustainable long-term.

The creator's casual "I hope I keep it lmao" reflects what many patients wonder about. Will the weight stay off? What happens if you stop the medication? His uncertainty is actually more honest than many GLP-1 success stories that skip over the maintenance reality.

What does the science say about keeping GLP-1 weight loss?

The data on this is pretty clear, and it's not what most people want to hear. Weight regain after stopping GLP-1 medications is the rule, not the exception.

The STEP 1 extension study (Rubino et al., Diabetes Care, 2021) followed patients who stopped semaglutide after 68 weeks of treatment. Those who switched to placebo regained 66% of their lost weight within 52 weeks. The STEP 4 withdrawal trial showed similar results: participants who stopped semaglutide regained 6.9% of their body weight while those who continued lost an additional 2.4%.

For tirzepatide, the SURMOUNT-4 trial (Jastreboff et al., Nature Medicine, 2022) showed that patients who stopped the medication after 36 weeks regained most of their weight loss. Those who continued tirzepatide maintained their 20.9% weight reduction.

What your grandfather got right and wrong

His uncertainty is actually spot-on with the science. Maintaining GLP-1 weight loss without continuing the medication is difficult for most people, and hoping isn't really a strategy.

But the video misses the bigger picture about what "keeping it" means. The research shows that staying on these medications long-term is typically necessary for sustained weight loss. The SELECT trial (Lincoff et al., NEJM, 2023) demonstrated that continued semaglutide use maintained cardiovascular benefits over 40 months, suggesting these aren't short-term fixes.

Your grandfather's casual approach doesn't acknowledge that successful maintenance usually requires ongoing medical management, not just hope and good intentions.

What patients actually need to know about GLP-1 maintenance

These medications work by changing how your brain responds to hunger and satiety signals. When you stop taking them, those changes largely reverse within months.

Real-world data from electronic health records shows that patients who stay on GLP-1 medications for two years maintain significantly more weight loss than those who stop early. The average person needs to think of these as long-term treatments, not temporary weight loss aids.

Some patients do maintain weight loss after stopping, but they're outliers. The STEP 1 data shows only about 20% of patients maintained their full weight loss one year after discontinuation. Most successful maintenance involves continued medication plus lifestyle changes.

The cost and insurance coverage issues your grandfather doesn't mention are real barriers. Many patients cycle on and off these medications based on coverage changes, creating a yo-yo pattern that's less effective than consistent treatment.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Your grandfather · TikTok creator

436.3K views on this video

I hope I keep it lmao

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about patients who stop glp-1 medications regain 60-70% of their weight?

Patients who stop GLP-1 medications regain 60-70% of their weight loss within one year according to multiple clinical trials

What does the video say about the step 4 withdrawal trial showed continued semaglutide users lost?

The STEP 4 withdrawal trial showed continued semaglutide users lost additional weight while those who stopped regained 6.9% body weight

What does the video say about surmount-4 data demonstrates?

SURMOUNT-4 data demonstrates that tirzepatide patients who stopped treatment regained most weight while continuing patients maintained 20.9% weight reduction

What does the video say about only about 20% of patients in step 1 maintained their?

Only about 20% of patients in STEP 1 maintained their full weight loss one year after stopping semaglutide

What does the video say about the select cardiovascular outcomes trial suggests these medications work best?

The SELECT cardiovascular outcomes trial suggests these medications work best as long-term treatments, not short-term fixes

What does the video say about real-world electronic health record data shows two-year continuous users maintain?

Real-world electronic health record data shows two-year continuous users maintain significantly more weight loss than early discontinuation patients

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Your grandfather, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.